Colgate-Palmolive Company $CL Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp lowered its holdings in Colgate-Palmolive Company (NYSE:CL) by 32.0% during the third quarter, Holdings Channel reports. The fund owned 162,684 shares of the company’s stock after selling 76,415 shares during the quarter. Boston Trust Walden Corp’s holdings in Colgate-Palmolive were worth $13,005,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Annex Advisory Services LLC grew its holdings in Colgate-Palmolive by 2.4% during the third quarter. Annex Advisory Services LLC now owns 106,068 shares of the company’s stock worth $8,479,000 after acquiring an additional 2,437 shares during the period. Goldstone Financial Group LLC boosted its position in Colgate-Palmolive by 18.4% in the 3rd quarter. Goldstone Financial Group LLC now owns 8,484 shares of the company’s stock worth $678,000 after purchasing an additional 1,319 shares in the last quarter. Traveka Wealth LLC grew its stake in shares of Colgate-Palmolive by 3.8% during the 3rd quarter. Traveka Wealth LLC now owns 4,979 shares of the company’s stock worth $398,000 after purchasing an additional 182 shares during the period. Three Seasons Wealth LLC purchased a new position in shares of Colgate-Palmolive during the 3rd quarter valued at approximately $552,000. Finally, PineStone Asset Management Inc. lifted its stake in shares of Colgate-Palmolive by 27.4% in the 3rd quarter. PineStone Asset Management Inc. now owns 1,604,089 shares of the company’s stock valued at $128,231,000 after purchasing an additional 344,700 shares during the period. 80.41% of the stock is owned by hedge funds and other institutional investors.

Colgate-Palmolive Stock Performance

NYSE CL opened at $79.51 on Wednesday. The company has a debt-to-equity ratio of 5.90, a current ratio of 0.93 and a quick ratio of 0.60. The stock’s 50 day simple moving average is $78.54 and its 200-day simple moving average is $82.46. The company has a market cap of $64.09 billion, a PE ratio of 22.27, a price-to-earnings-growth ratio of 5.68 and a beta of 0.30. Colgate-Palmolive Company has a 1-year low of $74.54 and a 1-year high of $100.18.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, October 31st. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.89 by $0.02. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.17 billion. Colgate-Palmolive had a return on equity of 333.39% and a net margin of 14.47%.The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 EPS. As a group, equities research analysts anticipate that Colgate-Palmolive Company will post 3.75 EPS for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 21st will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Wednesday, January 21st. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 58.26%.

Analysts Set New Price Targets

A number of research analysts have weighed in on CL shares. Evercore ISI cut their price objective on shares of Colgate-Palmolive from $100.00 to $94.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Wells Fargo & Company cut their price target on Colgate-Palmolive from $80.00 to $77.00 and set an “underweight” rating for the company in a research note on Monday, November 3rd. Citigroup lowered their price target on Colgate-Palmolive from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, November 3rd. Raymond James Financial cut their price objective on Colgate-Palmolive from $105.00 to $95.00 and set an “outperform” rating for the company in a research report on Monday, October 20th. Finally, The Goldman Sachs Group decreased their target price on Colgate-Palmolive from $106.00 to $91.00 and set a “buy” rating on the stock in a research report on Thursday, October 2nd. Ten investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.81.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.